Genentech, Chiron Settle Herceptin Patent Dispute
By Marius Meland · August 3, 2005, 12:00 AM EDT
Biotech companies Genentech, Inc. and Chiron have quietly settled the remaining patent disputes in a $300 million lawsuit over Genentech's metastatic breast cancer drug, Herceptin (Trastuzumab)....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login